Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.1
Certain groups are at increased risk of HCV infection. These include people who inject drugs, children born to mothers with HCV and recipients of infected blood products.2
From World Health Organization (WHO). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed January 2023.
The first-line test to aid in the diagnosis of HCV, delivering reliable, accurate results for patient-focused decision-making and a more efficient workflow.
The CDC now recommends one-time hepatitis C testing of all adults (18 years and older) and all pregnant women during every pregnancy. The CDC continues to recommend people with risk factors, including people who inject drugs, be tested regularly.6
Hepatitis C is curable in more than 95% of cases. People who test positive for hepatitis C should be treated with direct-acting antiviral (DAA) medication. Timely treatment is important to prevent liver damage and further spread. Treatment saves lives, prevents ongoing spread, and can save costs by stopping the disease from progressing.7
Proper diagnosis, along with viral load monitoring, allow healthcare professionals to optimally tailor therapy according to virus genotype, viral load (the amount of virus in the blood), and treatment response rate. By combining pharmaceutical and diagnostic innovations, we can deliver tangible benefits to patients more effectively.
Roche introduced the first-ever test to monitor HCV viral load in 1993 and remains committed to helping eradicate the virus today.
Roche assays support the accurate detection and viral-load quantification of HCV across different genotypes, helping clinicians make decisions that support the best patient care possible.
Empowering laboratories to balance productivity, efficiency, and potential cost effectiveness with fully automated and standardized workflows, on demand testing and the proven reliability of Roche quality results..
Unparalleled performance, absolute automation, and unmatched flexibility. Meet the needs of molecular testing today and experience the freedom to explore the possibilities for tomorrow.
Unparalleled performance with minimal operator interaction revolutionizes the future of highthroughput applications.
References
